Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

NCT02090075 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: apixaban
DRUG: warfarin

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center